Biotech IPOs offer investors a shot at exceptional returns but are often tricky for non-biochemists, which means most investors, to decipher.
So we reviewed 2018’s biotech, asking a basic question: are they developing innovative approaches to disease ...read more
Biotechs hold gold, silver and bronze in the 2018 IPO market.
Cancer immunotherapy devloper ARMO BioSciences (ARMO) is by far the year's best-performing IPO, up 200% from its offer price. Rounding out the podium is chronic itch biotech Menlo Therapeutics ...read more
Two small deals are on the calendar for the holiday week ahead, including single-asset Reg A+ IPO Aspen REIT and blank check company Crescent Funding. We expect IPO filing activity to pick up as we move through the annual mid-February lull...read more
A Novel Idea: Biotechs with Innovative Therapies Outperform
Biotech IPOs offer investors a shot at exceptional returns but are often tricky for non-biochemists, which means most investors, to decipher. So we reviewed 2018’s biotech, asking a basic question: are they developing innovative approaches to disease ...read more
What 2018’s IPOs Tell Us About 2H18
...read more
Biotechs take the podium with the year's 3 best IPOs
Biotechs hold gold, silver and bronze in the 2018 IPO market. Cancer immunotherapy devloper ARMO BioSciences (ARMO) is by far the year's best-performing IPO, up 200% from its offer price. Rounding out the podium is chronic itch biotech Menlo Therapeutics ...read more
US IPO Week Ahead: Look for a wave of filings in a quiet holiday week with 2 IPOs
Two small deals are on the calendar for the holiday week ahead, including single-asset Reg A+ IPO Aspen REIT and blank check company Crescent Funding. We expect IPO filing activity to pick up as we move through the annual mid-February lull...read more